Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

What Was Tested

The paper reports a study of Glucagon and Liraglutide, published as a randomized controlled trial.

First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

The timeline in the abstract includes 14 weeks.

What Was Measured

PubMed files the paper under topics including C-Peptide, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Hypoglycemic Agents, Incretins, Insulin Resistance and Islets of Langerhans.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Glucagon and Liraglutide over 14 weeks.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Glucagon compound page and the Liraglutide compound page, all human trials.